Early research (Phase 1)Study completedNCT00446654
What this trial is testing
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
Who this might be right for
Age Related Macular Degeneration
Progen Pharmaceuticals 43